KARPAS 231 Human B-cell Leukaemia cell line useful in oncology research, developed at the University of Cambridge.

Publications:

Nacheva et al. (1993). Blood 82, 231–240

Galieque Zouitina et al. (1996). Leukemia 10, 579–587

Willis et al. (1997). Blood 90, 2456–2464

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.